Despite substantial advances in the development of therapeutics focused on MAPK pathway inhibition in BRAF-mutated cancers, resistance and subsequent tumor relapse remain a major challenge to the durable success of these therapies [16]. The gene discussed is BRAF; the disease is neoplasm.